Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

VanEck Pharmaceutical ETF (NQ:PPH)

88.89 -0.33 (-0.37%)
Official Closing Price Updated: 4:15 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 493,545
Open 89.80
Bid (Size) 87.06 (29)
Ask (Size) 90.39 (28)
Prev. Close 89.22
Today's Range 88.83 - 90.85
52wk Range 84.48 - 99.51
Shares Outstanding N/A
Dividend Yield 1.84%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises
The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China. 
Via Stocktwits
Topics Earnings
Exposures Financial
Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report
Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5.1 billion. This growth is fueled by the global popularity of its weight-loss... 
Via Benzinga

Performance

YTD
+3.0%
+3.0%
1 Month
-6.0%
-6.0%
3 Month
+3.0%
+3.0%
6 Month
-5.5%
-5.5%
1 Year
+0.1%
+0.1%

More News

Read More
Just Say No to Drugs: 3 Pharma Stocks to Avoid
Via InvestorPlace
A Look At Pharma ETFs Post Q1 Earnings
Via Talk Markets
Topics ETFs
ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook
Via Talk Markets
Topics ETFs
VanEck Announces Year-End Distributions for VanEck Equity ETFs
From VanEck
Via Business Wire
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Via InvestorPlace
Topics ETFs
Novo Nordisk's Game-Changer: FDA Approves Weight Loss Sensation Wegovy For Heart Health, Potential Insurance Coverage
Via Benzinga
Exposures Product Safety
The Top 3 ETFs to Buy in March 2024
Via InvestorPlace
Topics ETFs
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
Via Benzinga
A Look At Pharma ETFs After Q4 Earnings
Via Talk Markets
Topics ETFs
5 ETF Zones Scaling New Highs At The Start Of 2024
Via Talk Markets
Topics ETFs
Government-granted Patent Monopolies Are Not The Free Market
Via Talk Markets
Topics Intellectual Property
Exposures Intellectual Property
Preparing For The Next Short-Term Rally Higher
Via Talk Markets
Pharma ETFs in Focus Post Q2 Earnings
Via Talk Markets
Topics ETFs
The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
Via InvestorPlace
Pharma ETFs Gain Post Q1 Earnings
Via Talk Markets
A Look At Pharma ETFs Post Q4 Earnings
Via Talk Markets
5 Sector ETFs That Beat The Market In December
Via Talk Markets
Pharma ETFs In Focus Post Q3 Earnings
Via Talk Markets
Wave of Solid Q3 Earnings Push Pharma ETFs Higher
Via Talk Markets
Pharma ETFs in Focus Post Q1 Earnings
Via Talk Markets

Frequently Asked Questions

Is VanEck Pharmaceutical ETF publicly traded?
Yes, VanEck Pharmaceutical ETF is publicly traded.
What exchange does VanEck Pharmaceutical ETF trade on?
VanEck Pharmaceutical ETF trades on the Nasdaq Stock Market
What is the ticker symbol for VanEck Pharmaceutical ETF?
The ticker symbol for VanEck Pharmaceutical ETF is PPH on the Nasdaq Stock Market
What is the current price of VanEck Pharmaceutical ETF?
The current price of VanEck Pharmaceutical ETF is 88.89
When was VanEck Pharmaceutical ETF last traded?
The last trade of VanEck Pharmaceutical ETF was at 04/03/25 04:15 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.